Skip to main content
Erschienen in: Clinical Research in Cardiology 11/2008

01.11.2008 | ORIGINAL PAPER

Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?

verfasst von: K. Ibrahim, N. Hass, S. Kolschmann, R. H. Strasser, R. C. Braun-Dullaeus

Erschienen in: Clinical Research in Cardiology | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

A 63-year-old male Patient was admitted to the intensive care unit due to acute inferior myocardial infarction with right ventricular dysfunction. He received a loading dose of clopidogrel (600 mg) and aspirin (500 mg) and was immediately revascularized by reopening of the proximal right coronary artery (RCA) and implantation of a bare metal stent. After primary successful intervention the patient suffered from thoracic pain on day 5 of admission. The ECG indicated reinfarction. The proximal RCA was again re-opended by PTCA alone. The following day the patient suffered again from thoracic pain with ST-elevation in the inferior leads, this time complicated by additional total AV-blockade. The angiography showed another time a thrombotic occlusion of the initially implanted stent. He received another intervention with implantation of additional two baremetal stents, an aortic counter-pulsation and a temporary two-chamber pace maker. Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h. The patient was discharged on Aspirin 300 mg/d, Clopidogrel 150 mg/d and Enoxaparin 40 mg/d. Six weeks later the patient demonstrated an improved right ventricular function (TAPSE 18 mm), liver enzymes were normal, and inhibition of platelet aggregation by clopidogrel (150 mg/d) was sufficient. In conclusion this implies that the reversible “clopidogrel-resistance” might have been due to congestion and reduced metabolism due to right ventricular infarction.
Literatur
1.
Zurück zum Zitat Angiolillo DJ, et al. (2007) Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol 49:1505–1516PubMedCrossRef Angiolillo DJ, et al. (2007) Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol 49:1505–1516PubMedCrossRef
2.
Zurück zum Zitat Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. (2004) Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16:169–174PubMed Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. (2004) Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16:169–174PubMed
3.
Zurück zum Zitat Angiolillo, Fernandez-Ortiz, Bernardo, et al. (2005) Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430–2435 Angiolillo, Fernandez-Ortiz, Bernardo, et al. (2005) Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430–2435
4.
Zurück zum Zitat Ellis et al. (2007) Incidence, timing and correlates of stentthombosis with the polymeric paclitaxel drug eluting stent. J Am Coll Cardiol 49:1043–1051 Ellis et al. (2007) Incidence, timing and correlates of stentthombosis with the polymeric paclitaxel drug eluting stent. J Am Coll Cardiol 49:1043–1051
5.
Zurück zum Zitat Fontana D (2003) ADP induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989–995 Fontana D (2003) ADP induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989–995
6.
Zurück zum Zitat Smith SC, et al. (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article. J Am Coll Cardiol 47:216–235PubMedCrossRef Smith SC, et al. (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article. J Am Coll Cardiol 47:216–235PubMedCrossRef
7.
Zurück zum Zitat Soffer D, Moussa I, Harjai KJ, et al. (2003) Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 59:21–25PubMedCrossRef Soffer D, Moussa I, Harjai KJ, et al. (2003) Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 59:21–25PubMedCrossRef
8.
Zurück zum Zitat Spaulding et al. (2006) Sirolimus-eluting versus uncoated stents in acute myocaridal infarction. N Engl J Med 355:1093–1104 Spaulding et al. (2006) Sirolimus-eluting versus uncoated stents in acute myocaridal infarction. N Engl J Med 355:1093–1104
9.
Zurück zum Zitat Spertus et al. (2006) Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement. Results from the PREMIER registry. Circulation 113:2803 Spertus et al. (2006) Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement. Results from the PREMIER registry. Circulation 113:2803
Metadaten
Titel
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
verfasst von
K. Ibrahim
N. Hass
S. Kolschmann
R. H. Strasser
R. C. Braun-Dullaeus
Publikationsdatum
01.11.2008
Verlag
D. Steinkopff-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 11/2008
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-008-0679-0

Weitere Artikel der Ausgabe 11/2008

Clinical Research in Cardiology 11/2008 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.